Eli Lilly: After Prozac, another big hit

Novo Nordisk may have spearheaded the weight-loss drug bonanza when it unleashed Ozempic on an extremely grateful US market in 2017, but Eli Lilly has joined the party with gusto. Its major headache is how to construct production lines to churn out the gut-busters fast enough to satisfy demand. ..

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.